Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor

FDA approved pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test.  October 24, 2016.



No comments have been posted yet.